The rate of discontinuation is high, and the root cause is unclear.
Often, in clinical practice, we may not even be aware of whether people are continuing to take their medications. Trials, with intensive evaluations of motivated participants, likely have the highest levels of medication adherence and provide helpful data from the placebo arms. These researchers analyzed results from IMPROVE-IT, which routinely evaluated discontinuation of medications over 7 years in the study's comparison of ezetimibe + simvastatin with placebo + simvastatin among patients with recent acute coronary syndrome.
Over the course of the trial, 47% of the participants discontinued the study medication. Even by 30 days, 6% had discontinued the study medication; another 14% had discontinued by 1 year. Discontinuation in the placebo…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association